SPARC jumps 8% on successful pivotal bioequivalence study for cancer drughttps://www.moneycontrol.com/news/business/markets/sparc-jumps-8-on-successful-pivotal-bioequivalence-study-for-cancer-drug-3218341.html#SPARC